Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial-Reference-Cited by-同舟云学术

Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial

Published:2014-06 Issue:6 Volume:191 Page:1721-1727
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kauf Teresa L.¹,Svatek Robert S.²,Amiel Gilad³,Beard Timothy L.⁴,Chang Sam S.⁵,Fergany Amr⁶,Karnes R. Jeffrey⁷,Koch Michael⁸,O'Hara Jerome⁶,Lee Cheryl T.⁹,Sexton Wade J.¹⁰,Slaton Joel W.¹¹,Steinberg Gary D.¹²,Wilson Shandra S.¹³,Techner Lee¹,Martin Carolyn¹⁴,Moreno Jessica¹,Kamat Ashish M.¹⁵

Affiliation:

1. Cubist Pharmaceuticals, Lexington, Massachusetts

2. University of Texas Health Science Center at San Antonio, San Antonio, Texas

3. Baylor University, Baylor College of Medicine, Houston, Texas

4. Bend Memorial Clinic, Bend, Oregon

5. Vanderbilt University Medical Center, Nashville, Tennessee

6. Cleveland Clinic Foundation, Cleveland, Ohio

7. Mayo Clinic, Rochester, Minnesota

8. Indiana University Medical Center, Indianapolis, Indiana

9. University of Michigan, Ann Arbor, Michigan

10. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

11. University of Oklahoma College of Medicine, Oklahoma City, Oklahoma